Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, Li D, Zhang XY, Liu JL, Li JL. Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis. World J Gastroenterol 2014; 20(4): 1095-1106 [PMID: 24574784 DOI: 10.3748/wjg.v20.i4.1095]
Corresponding Author of This Article
Zheng-Xu Wang, MD, PhD, Associate Professor, Director of Biotherapy Center, the General Hospital of Beijing Military Command, No.5 of Nan Men Cang Rd, Dongcheng District, Beijing 100700, China. zhxwang18@hotmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 28, 2014; 20(4): 1095-1106 Published online Jan 28, 2014. doi: 10.3748/wjg.v20.i4.1095
Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis
Zheng-Xu Wang, Jun-Xia Cao, Zhi-Ping Liu, Yu-Xin Cui, Chun-Yun Li, Duo Li, Xiao-Yan Zhang, Jin-Long Liu, Jun-Li Li
Zheng-Xu Wang, Jun-Xia Cao, Chun-Yun Li, Duo Li, Xiao-Yan Zhang, Jin-Long Liu, Jun-Li Li, Biotherapy Center, the General Hospital of Beijing Military Command, Beijing 100700, China
Zhi-Ping Liu, Department of Immunology, St Jude Children’s Research Hospital, Memphis, TN 38105, United States
Yu-Xin Cui, School of Cellular and Molecular Medicine, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom
Author contributions: Wang ZX designed the research; Cao JX and Li CY performed the research; Liu ZP and Cui YX contributed new reagents or analytic tools; Cao JX, Li CY, Li D, Zhang XY, Liu JL and Li JL analyzed data; Wang ZX, Cao JX, Liu ZP and Cui YX wrote the paper.
Supported by National Natural Science Foundation of China, No. 31171427 and No. 30971651 to Wang ZX; National Natural Science Foundation of China, No. 30700974 to Cao JX; and Postdoctoral Foundation of China, No. 20060400775 to Cao JX
Correspondence to: Zheng-Xu Wang, MD, PhD, Associate Professor, Director of Biotherapy Center, the General Hospital of Beijing Military Command, No.5 of Nan Men Cang Rd, Dongcheng District, Beijing 100700, China. zhxwang18@hotmail.com
Telephone: +86-10-66721169 Fax: +86-10-64038276
Received: September 10, 2013 Revised: October 28, 2013 Accepted: November 12, 2013 Published online: January 28, 2014 Processing time: 138 Days and 9.1 Hours
Core Tip
Core tip: A growing body of knowledge on tumor immunosurveillance and loss thereof has contributed to the refinement of anti-tumor immunotherapy. The aim of our meta-analysis was to determine whether an association exists between dendritic cell (DC)-cytokine-induced killer (CIK) cell therapy combined with chemotherapy and chemotherapy alone. Our analysis demonstrates that DC-CIK therapy improved 1, 2 and 3-year overall survival, 1, 2 and 3-year disease-free survival, overall response rate and immune indices in colon cancer. In all, the combination of DC-CIK immunotherapy and chemotherapy was superior in prolonging the survival time and enhancing immunological responses, suggesting the possible application of this promising adjuvant immunotherapy in colon cancer.
